Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al
Support During Weakness & Recovery
Protocol 2: Intermediate approach (experienced researchers) Goal: Multi-target immune modulation with anti-inflammatory support Components: Thymosin alpha-1: 1.6 mg subcutaneously, three times weekly KPV: 200-500 mcg subcutaneously, once daily BPC-157: 250 mcg subcutaneously, twice daily Selank: 250-500 mcg intranasally, once daily Schedule: Monday, Wednesday, Friday: Thymosin alpha-1 Daily AM: KPV + BPC-157 Daily PM: BPC-157 Daily: Selank nasal spray (morning or midday) Duration: 12 weeks on, 4 weeks off Monitoring: Baseline labs, repeat every 4 weeks
Researchers planning new work should review the most current literature before designing protocols, with attention to the gap between preclinical breadth and clinical-trial depth